At the 2014 American Diabetes Association Scientific Sessions, Eli Lilly and Company presented favorable results from dulaglutide’s AWARD-6 trial.
AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) is a Phase 3 non-inferiority study that compared the safety and efficacy of dulaglutide and liraglutide (Victoza; Novo Nordisk), two glucagon-like peptide-1 (GLP-1) receptor agonists. The study demonstrated that dulaglutide 1.5mg once weekly was non-inferior to liraglutide 1.8mg once-daily. Similar reductions in HbA1c levels were seen across both treatment arms.
At 26 weeks, dulaglutide 1.5mg once-weekly and liraglutide 1.8mg once-daily reduced HbA1c levels from baseline (-1.42% and -1.36%, respectively), with dulaglutide showing non-inferiority vs. liraglutide. Also, patients treated with dulaglutide and liraglutide showed significant weight reductions from baseline (-2.9kg and -3.6kg, respectively). Rates of hypoglycemia were similar between patients in the dulaglutide (0.34 events/patients/year) and liraglutide (0.52 events/patients/year) group.
If dulaglutide is granted FDA approval, it will be marketed under the brand name Trulicity.
For more information visit Lilly.com.